Type 2 diabetes mellitus (T2DM) is mainly associated with impaired insulin secretion by the pancreatic β-cells, insulin resistance and elevated hepatic gluconeogenesis. Incretin based treatments for T2DM are now widely investigated and used. The incretin based therapies mainly include incretin hormones which are glucose-dependent insulinotropic peptides (GIP) and glucagon like peptide-1 (GLP-1) released from the endocrinal cells in the small intestine in response to food intake. The main function of GLP-1 is to induce insulin secretion and suppress glucagon secretion. This review describes the different formulation approaches for oral delivery of incretins and the limitations associated with this route of administration. We highlight the use of micro and nanosystems to efficiently deliver the incretins orally. Furthermore, we present several examples of the significant potential of these systems in pharmaceutical applications.
Keywords: Glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 (GLP-1), incretins, lipids, microparticles, mesoporous materials, nanoparticles, oral drug delivery, polymers.
Non-Alcoholic Fatty Pancreas Disease (NAFPD): A Silent Spectator or the Fifth Component of Metabolic Syndrome? A Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Edaravone (3-Methyl-1-Phenyl-2-Pyrazolin-5-one), A Novel Free Radical Scavenger, for Treatment of Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Coenzyme Q10 in Cardiovascular and Metabolic Diseases: Current State of the Problem
Current Cardiology Reviews Advances in Antidiabetic Drugs Targeting Insulin Secretion
Current Pharmaceutical Design The Heat Stress Response and Diabetes: More Room for Mitochondrial Implication
Current Pharmaceutical Design Impact of Seasonality on Gestational Diabetes Mellitus
Endocrine, Metabolic & Immune Disorders - Drug Targets Sirtuins: Developing Innovative Treatments for Aged-Related Memory Loss and Alzheimer’s Disease
Current Neurovascular Research Cardiovascular Diseases and the Nitric Oxide Pathway
Current Vascular Pharmacology Synergy of microRNA and Stem Cell: A Novel Therapeutic Approach for Diabetes Mellitus and Cardiovascular Diseases
Current Diabetes Reviews Canagliflozin : A New Hope in the Antidiabetic Armamentarium
Recent Patents on Cardiovascular Drug Discovery (Discontinued) Gene-Diet Interactions in Childhood Obesity
Current Genomics Perioperative Glycemic Management in Insulin Pump Patients Undergoing Noncardiac Surgery
Current Pharmaceutical Design Should Cushing’s Syndrome be Considered as a Disease with High Cardiovascular Risk in Relevant Guidelines?
Current Vascular Pharmacology Visfatin: Structure, Function and Relation to Diabetes Mellitus and Other Dysfunctions
Current Medicinal Chemistry The Extra-Hematopoietic Role of Erythropoietin in Diabetes Mellitus
Current Diabetes Reviews Effects of PPARγ Ligands on Vascular Tone
Current Molecular Pharmacology The Pathogenic Role of Persistent Milk Signaling in mTORC1- and Milk- MicroRNA-Driven Type 2 Diabetes Mellitus
Current Diabetes Reviews Platelets and Platelet-Derived Microvesicles as Immune Effectors in Type 2 Diabetes
Current Vascular Pharmacology Alginates in Pharmaceutics and Biomedicine: Is the Future so Bright?
Current Pharmaceutical Design